These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 36154355)

  • 1. Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma.
    Ged Y; Lee CH
    Expert Rev Anticancer Ther; 2022 Oct; 22(10):1049-1059. PubMed ID: 36154355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
    Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ
    Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma.
    Jacob A; Shook J; Hutson T
    Expert Rev Anticancer Ther; 2021 Apr; 21(4):365-372. PubMed ID: 33393393
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and toxicity of immune checkpoint inhibitors combination therapy for advanced renal cell carcinoma: a systematic review and network meta-analysis.
    Chen X; Xu Z; Wu C; Xie L; Wang P; Liu X
    Front Immunol; 2024; 15():1255577. PubMed ID: 38390328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenvatinib for the treatment of kidney cancer.
    Študentová H; Vitásková D; Melichar B
    Expert Rev Anticancer Ther; 2018 Jun; 18(6):511-518. PubMed ID: 29737893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale.
    Grünwald V; Powles T; Choueiri TK; Hutson TE; Porta C; Eto M; Sternberg CN; Rha SY; He CS; Dutcus CE; Smith A; Dutta L; Mody K; Motzer RJ
    Future Oncol; 2019 Mar; 15(9):929-941. PubMed ID: 30689402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
    Motzer R; Alekseev B; Rha SY; Porta C; Eto M; Powles T; Grünwald V; Hutson TE; Kopyltsov E; Méndez-Vidal MJ; Kozlov V; Alyasova A; Hong SH; Kapoor A; Alonso Gordoa T; Merchan JR; Winquist E; Maroto P; Goh JC; Kim M; Gurney H; Patel V; Peer A; Procopio G; Takagi T; Melichar B; Rolland F; De Giorgi U; Wong S; Bedke J; Schmidinger M; Dutcus CE; Smith AD; Dutta L; Mody K; Perini RF; Xing D; Choueiri TK;
    N Engl J Med; 2021 Apr; 384(14):1289-1300. PubMed ID: 33616314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.
    Taylor MH; Lee CH; Makker V; Rasco D; Dutcus CE; Wu J; Stepan DE; Shumaker RC; Motzer RJ
    J Clin Oncol; 2020 Apr; 38(11):1154-1163. PubMed ID: 31961766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab.
    Lee CH; DiNatale RG; Chowell D; Krishna C; Makarov V; Valero C; Vuong L; Lee M; Weiss K; Hoen D; Morris L; Reznik E; Murray S; Kotecha R; Voss MH; Carlo MI; Feldman D; Sachdev P; Adachi Y; Minoshima Y; Matsui J; Funahashi Y; Nomoto K; Hakimi AA; Motzer RJ; Chan TA
    Mol Cancer Res; 2021 Sep; 19(9):1510-1521. PubMed ID: 34039647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced Renal Cell Carcinoma With Inferior Vena Cava Thrombus Treated With a Combination of Preoperative Lenvatinib and Pembrolizumab.
    Nagahisa C; Yoshida K; Kondo H; Nakayama T; Mizoguchi S; Minoda R; Fukuda H; Kobari Y; Iizuka J; Nagashima Y; Ishida H; Takagi T
    Anticancer Res; 2024 Mar; 44(3):1317-1321. PubMed ID: 38423655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myocarditis Following Pembrolizumab Plus Axitinib, and Belzutifan Plus Lenvatinib for Renal Cell Carcinoma: A Case Report.
    Villatore A; Bosi C; Pomaranzi C; Cigliola A; Tateo V; Mercinelli C; Vignale D; Rizzo S; Necchi A; Peretto G
    Cardiovasc Toxicol; 2024 Nov; 24(11):1168-1173. PubMed ID: 39085529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population.
    Fujiwara R; Yuasa T; Kobayashi K; Yoshida T; Kageyama S
    Expert Rev Anticancer Ther; 2023 May; 23(5):461-469. PubMed ID: 37038721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study.
    Motzer RJ; Choueiri TK; Hutson T; Young Rha S; Puente J; Lalani AA; Winquist E; Eto M; Basappa NS; Tannir NM; Vaishampayan U; Bjarnason GA; Oudard S; Grünwald V; Burgents J; Xie R; McKenzie J; Powles T
    Eur Urol; 2024 Jul; 86(1):4-9. PubMed ID: 38582713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New drug approval: Lenvatinib plus pembrolizumab for advanced renal cell carcinoma].
    Saillant A; Borchiellini D
    Bull Cancer; 2022; 109(7-8):737-738. PubMed ID: 35599170
    [No Abstract]   [Full Text] [Related]  

  • 15. Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy?
    De Lisi D; De Giorgi U; Lolli C; Schepisi G; Conteduca V; Menna C; Tonini G; Santini D; Farolfi A
    Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):461-467. PubMed ID: 29557694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
    Motzer RJ; Porta C; Eto M; Powles T; Grünwald V; Hutson TE; Alekseev B; Rha SY; Merchan J; Goh JC; Lalani AA; De Giorgi U; Melichar B; Hong SH; Gurney H; Méndez-Vidal MJ; Kopyltsov E; Tjulandin S; Gordoa TA; Kozlov V; Alyasova A; Winquist E; Maroto P; Kim M; Peer A; Procopio G; Takagi T; Wong S; Bedke J; Schmidinger M; Rodriguez-Lopez K; Burgents J; He C; Okpara CE; McKenzie J; Choueiri TK;
    J Clin Oncol; 2024 Apr; 42(11):1222-1228. PubMed ID: 38227898
    [No Abstract]   [Full Text] [Related]  

  • 17. Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma.
    Spisarová M; Melichar B; Vitásková D; Študentová H
    Expert Rev Anticancer Ther; 2021 Jul; 21(7):693-703. PubMed ID: 33794744
    [No Abstract]   [Full Text] [Related]  

  • 18. First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC.
    Romero D
    Nat Rev Clin Oncol; 2023 Oct; 20(10):661. PubMed ID: 37507496
    [No Abstract]   [Full Text] [Related]  

  • 19. Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.
    Matsubara N; de Wit R; Balar AV; Siefker-Radtke AO; Zolnierek J; Csoszi T; Shin SJ; Park SH; Atduev V; Gumus M; Su YL; Karaca SB; Cutuli HJ; Sendur MAN; Shen L; O'Hara K; Okpara CE; Franco S; Moreno BH; Grivas P; Loriot Y
    Eur Urol; 2024 Mar; 85(3):229-238. PubMed ID: 37778952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma.
    Grande E; Glen H; Aller J; Argenziano G; Lamas MJ; Ruszniewski P; Zamorano JL; Edmonds K; Sarker S; Staehler M; Larkin J
    Expert Opin Drug Saf; 2017 Dec; 16(12):1413-1426. PubMed ID: 28920492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.